Byung‐Kun Kim

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

Vladimir Skljarevski, Manjit Matharu, Brian A. Millen et al. · Cephalalgia · 2018 · 557 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Wim M. Mulleners, Byung‐Kun Kim, Miguel J. A. Láinez et al. · The Lancet Neurology · 2020 · 283 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Clinical Characteristics of Benign Paroxysmal Positional Vertigo in Korea: A Multicenter Study

So Young Moon, Ji Soo Kim, Byung‐Kun Kim et al. · Journal of Korean Medical Science · 2006 · 135 citations · Full text

Medicine, Neurology, Otolaryngology +15

Risk Factors of Intracranial Cerebral Atherosclerosis among Asymptomatics

Hee‐Joon Bae, Juneyoung Lee, Jong‐Moo Park et al. · Cerebrovascular Diseases · 2007 · 126 citations

Medicine, Neurology, Epidemiology +11

Randomized clinical trial for geotropic horizontal canal benign paroxysmal positional vertigo

Ji Soo Kim, Sun‐Young Oh, Seung‐Han Lee et al. · Neurology · 2012 · 117 citations

Medicine, Otolaryngology, Neurotology +11